<DOC>
	<DOC>NCT01994486</DOC>
	<brief_summary>This is an open-label, multi center study of treatment-naive non-cirrhotic subjects with genotype 1 chronic Hepatitis C Virus. All subjects will receive telaprevir (TVR) in combination with sofosbuvir (SOF) for 12 weeks.</brief_summary>
	<brief_title>Open-Label Safety Study of Telaprevir and Sofosbuvir in Chronic Hepatitis C Genotype 1</brief_title>
	<detailed_description>Starting on Day 1 and for up to 12 weeks, you will receive Telaprevir (TVR) and Sofosbuvir (SOF). You will take one (1) 400 mg tablet of SOF and 3 tablets (1125 mg each) of TVR. You should take these together by mouth every morning. You will take another 3 tablets (1125 mg each) of TVR by mouth 12 hours after you take your morning dose.</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Willing and able to provide informed consent BMI (Body Mass Index) ≥ 18 kg/m2 HCV RNA quantifiable at screening and &gt;1,000 IU/ml HCV treatment Naïve HCV genotype 1 7. Confirmation of chronic HCV infection documented by either: A positive antiHCV antibody test or positive HCV RNA or positive HCV genotyping test at least 6 months prior to the Baseline/Day 1 visit, or A liver biopsy performed prior to the Baseline/Day 1 visit with evidence of chronic HCV infection Current or prior history of any of the following: Clinicallysignificant illness Cirrhosis 2. Screening ECG with clinically significant abnormalities 1. ALT &gt; 10 x the upper limit of normal (ULN) 2. AST &gt; 10 x ULN 3. Direct bilirubin &gt; 1.5 x ULN 4. Platelets &lt; 150,000/μL 5. HbA1c &gt; 7.5% 6. Creatinine clearance (CLcr) &lt; 60 mL /min, as calculated by the CockcroftGault equation 7. Hemoglobin &lt; 11 g/dL for female subjects; &lt; 12 g/dL for male subjects. 8. Albumin &lt; 3.1 g/dL 9. INR &gt; 1.5 x ULN unless subject has known hemophilia or is stable on an anticoagulant regimen affecting INR 4. Prior exposure to any approved or experimental HCVspecific directacting 5. Pregnant or nursing female or male with pregnant female partner. 6. Chronic liver disease of a nonHCV etiology (e.g., hemochromatosis, Wilson's disease, alfa1 antitrypsin deficiency, cholangitis). 7. Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>HCV Genotype 1</keyword>
	<keyword>Hepatitis C Virus Genotype 1</keyword>
	<keyword>HCV</keyword>
	<keyword>TVR</keyword>
</DOC>